Abstract

A pharmaceutical composition comprising:

(a) an anticholinergic selected from glycopyrronium bromide or an ester of a bi- or tricyclic amino alcohol of formula (I)

$$z$$
 O
 Q
 N^{\dagger}
 $R'_{(I)}$

wherein: Q, R, R', and Z are definded in the claims and an equivalent of an anion X counters the positive charge of the N atom; and

(b) a betamimetic selected from the group consisting of: formoterol; salmeterol; 4-hydroxy-7-[2-{[2-{[3-(2-phenylethoxy)propyl]sulfonyl}ethyl]amino}ethyl]-2(3*H*)-benzothiazolone; 1-(2-fluoro-4-hydroxyphenyl)-2-[4-(1-benzimidazolyl)-2-methyl-2-butylamino]ethanol; 1-[3-(4-methoxybenzylamino)-4-hydroxyphenyl]-2-[4-(1-benzimidazolyl)-2-methyl-2-butylamino]ethanol; 1-[2*H*-5-hydroxy-3-oxo-4*H*-1,4-benzoxazin-8-yl]-2-[3-(4-*N*,*N*-dimethylaminophenyl)-2-methyl-2-propylamino]ethanol; 1-[2*H*-5-hydroxy-3-oxo-4*H*-1,4-benzoxazin-8-yl]-2-[3-(4-*n*-butyloxyphenyl)-2-methyl-2-propylamino]ethanol; and 1-[2*H*-5-hydroxy-3-oxo-4*H*-1,4-benzoxazin-8-yl]-2-{4-[3-(4-methoxyphenyl)-1,2,4-triazol-3-yl]-2-methyl-2-butylamino}ethanol, and a pharmacologically compatible acid addition salt thereof,

and its use in the therapy of respiratory ailments.